BioDlink Named "Emerging CDMO of the Year" at the 2026 Asia-Pacific Biopharma Excellence Awards

 BioDlink, an innovation-driven Contract Development and Manufacturing Organization (CDMO), announced that it has been named "Emerging CDMO of the Year" at the Asia-Pacific Biopharma Excellence Awards, organized by IMAPAC.

Presented by IMAPAC, the Asia-Pacific Biopharma Excellence Awards celebrate excellence and innovation across the biopharmaceutical industry in the Asia-Pacific region. The awards recognize organizations that demonstrate outstanding technological capabilities, operational excellence, and leadership in advancing biopharma development and manufacturing. By honoring these achievements, the program highlights companies that are shaping the future of the global biopharma ecosystem.

The recognition underscores BioDlink's growing role as a trusted development and manufacturing partner for global biopharmaceutical innovators. The company provides integrated solutions for complex biologics and antibody-drug conjugates (ADCs), supporting programs from early research and technology evaluation through process development, analytical development and manufacturing.

BioDlink's capabilities are supported by a portfolio of proprietary technology platforms designed to enhance development efficiency and scalability. These include GL-DisacLink^®, a co-developed conjugation platform that simplifies ADC manufacturing through a streamlined enzyme-based conjugation strategy; BDKcell™, a cell line development platform delivering high-expression performance in standard fed-batch processes across multiple biologic modalities, including monoclonal antibodies, bispecific antibodies, fusion proteins, and nanobodies; and BDKLyo, a digital-intelligent lyophilization process calculation platform that uses predictive modeling to accelerate development and enable more efficient scale-up, helping partners reach critical production milestones with greater speed and confidence.

Complementing technology platforms, BioDlink continues to expand its development and manufacturing infrastructure to support global programs across multiple development stages. The company offers scalable production capabilities for complex biologics, enabling efficient progression from early development to manufacturing while maintaining consistent quality standards.